Serbia's medicines regulator, founded in 2004. It authorises medicines and clinical trials, and the law gives it an accelerated route, with a 150-day limit, for medicines already authorised through the EU centralised procedure.
The Medicines and Medical Devices Agency of Serbia was founded on 1 October 2004 under the Law on Medicines and Medical Devices, taking over the assets of the former Institute of Pharmacy of Serbia. It authorises medicines and medical devices, approves clinical trials, controls quality and runs pharmacovigilance. The coordinates are an approximate Belgrade city point.
The current Law on Medicines and Medical Devices (Official Gazette 30/2010, amended 2012 and 2017) requires the Agency to decide on a complete marketing authorisation application within 210 days, with the clock stopped while it waits for answers. Article 34 provides an accelerated procedure, with a 150-day limit, for a medicine of the highest public health interest, above all a therapeutic innovation, and for a medicine already authorised through the EU centralised procedure; article 35 allows a conditional authorisation for 12 months at a time for serious and life-threatening diseases, rare diseases and centrally authorised medicines. The law treats EU countries and members of the International Council for Harmonisation as having the same or similar authorisation requirements.
In July 2019 the Agency announced that the World Health Organization had confirmed, after checking 285 indicators in nine areas, that Serbia's national regulatory authority (the Ministry of Health, the Agency and the Batut institute) could be ranked among the 50 best in the world for regulating medicines and vaccines. The announcement does not name a maturity level, and OnCo did not read WHO's own list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/